Crystal form of acalabrutinib and preparation method and use thereof
US11091494B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2018 |
| Grant date | Aug 17, 2021 |
| Priority date | — |
| Expiry date | Nov 20, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to novel crystalline forms of acalabrutinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing acalabrutinib, use of acalabrutinib for preparing Bruton's tyrosine kinase inhibitor drug, and use of acalabrutinib for preparing drugs treating mantle cell lymphoma. The crystalline forms of the present disclosure have one or more improved properties compared with prior art, and have significant value for future drug optimization and development.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.